Mohammed E. Elsalanty, Ph.D.

MCTS - Master of Clinical and Translational Studies, Augusta University, Georgia, 2010

PhD - Biomedical Sciences, Texas A&M University System, Baylor College of Dentistry, Texas, 2004

MBBS - Medical Bachelor and Bachelor of Surgery, Cairo University Medical School, Cairo Egypt, 1994

Post-Doctoral Training, Texas A&M University System, Baylor College of Dentistry, 2004-2007

USMLE, United States Medical Licensure Examination, 2005

Academic Appointments

July 2020 -Professor and Chairman,Medical Anatomy Department, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California, USA, 91766

2018-2020 -Professor, Dental College of Georgia, Augusta University: Department of Oral Biology, Department of Oral and Maxillofacial Surgery, Department of Cellular Biology and Anatomy, and Graduate School; Lecturer and instructor in microanatomy, Head and Neck Anatomy, Developmental Biology, Neuroscience, and multiple other courses.

2012-2018 -Associate Professor, Dental College of Georgia, Augusta University: Department of Oral Biology, Department of Oral and Maxillofacial Surgery, Department of Cellular Biology and Anatomy, and Graduate School; Lecturer and instructor in microanatomy, Head and Neck Anatomy, Developmental Biology, Neuroscience, and multiple other courses.

2007-2012 -Assistant Professor, Dental College of Georgia, Augusta University: Department of Oral Biology, Department of Oral and Maxillofacial Surgery, Department of Cellular Biology and Anatomy, and Graduate School; Lecturer and instructor in microanatomy, Head and Neck Anatomy, Developmental Biology, Neuroscience, and multiple other courses.

2005-2007 -Assistant Research Scientist, Texas A&M University System Health Science Center, Center for Craniofacial Research and Diagnosis, Department of Biomedical Sciences, Baylor College of Dentistry, Dallas, Texas, USA.

2004-2005 -Postdoctoral Fellow, Texas A&M University System Health Science Center, Center for Craniofacial Research and Diagnosis, Department of Biomedical Sciences, Baylor College of Dentistry, Dallas, Texas, USA.

2001-2004 - PhD Student, Texas A&M University System Health Science Center, Center For Craniofacial Research and Diagnosis, Department of Biomedical Sciences, Baylor College of Dentistry, Dallas, Texas, USA.

1997-2001 - Resident in Orthopedic and Maxillofacial Surgery Departments; Nasser Institute Hospital, Cairo, Egypt.

1996-1997 - General practitioner, Egyptian Army units, Cairo, Egypt.

1994-1996 - House Officer; Cairo University Hospitals, Cairo, Egypt.

Other Professional Experience

1/2020 - 6/2020 - Visiting Professor and Chairman: Medical Biotechnology Department, College of Biotechnology, Misr University for Science and Technology, Cairo, Egypt

The oral cavity is one of the unique microenvironments in the body. The interactions between alveolar bone, dental tissues, oral mucosa, oral bacteria, immune cells, and saliva define several physiological and pathological processes that are specific to the oral cavity. Alveolar bone shows unique patterns of adaptation to mechanical loading, disuse, aging, and remodeling-altering medications, especially bisphosphonates. Dr. Elsalanty’s lab has been investigating the interaction between alveolar bone and the soft tissues during regeneration and mechanical loading. Recently, his team has focused on exploring the mechanisms for medication-associated osteonecrosis of the jaw (ONJ), as a venue to explore the mechanisms that make the condition exclusive to jawbones, as well as developing strategies for preventing such a serious condition. They are currently exploring the unique response of alveolar bone to anti-resorptive medications from three interconnected directions. The first is to investigate the role of matrix-bound bisphosphonates in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). The hypothesis is that bisphosphonate molecules that become embedded into the bone matrix remain accessible and biologically active and they affect bone homeostasis through the impairment of osteoclast and osteocyte functions. The second direction is to investigate the effects of bisphosphonates on osteoclast-mediated angiogenesis in alveolar bone. Strong preliminary data support the hypothesis that bisphosphonates impair post-extraction angiogenesis in the jaw. We are currently investigating the effect of bisphosphonates on PDGF-BB pathway in pre-osteoclasts, and whether this pathway plays a role in post-extraction angiogenesis. The third direction is to study the effect of matrix-bound bisphosphonates on biofilm formation and localized immune response in the jaw. Preliminary data shows that bisphosphonate-treated animals have higher bacterial content in the oral cavity under baseline conditions. The long-term goal is to uncover mechanisms by which alveolar bone reacts to pathological conditions and aging-related changes and develop strategies to extend the health-span of musculoskeletal tissues.

Recent Research Grant History

2R15 DE025134-02, National Institute of Dental and Craniofacial Research, Mohammed Elsalanty (PI), 09/15/2018 – 09/14/2021

S10 OD025177-01, National Institute of Health, Mohammed Elsalanty (PI), 06/01/2018-05/31/2019

2P01 AG036675-06A1, National Institute on Aging, Carlos Isalis (PI), 05/01/11-04/30/22

1R15 DE025134-01, National Institute of Dental and Craniofacial Research, Mohammed Elsalanty (PI), 03/01/2015-02/28/2019

2017 - Excellence in Teaching Award, Dental College of Georgia

2017 – Kappa Lambda Chapter of Omicron Kappa Epsilon.

2014 – Phi Kappa Phi

2012 – Inducted to the Augusta University Academy of Health Sciences Educators

2005 - Nominated for the 2005 Technology Review Magazine TR35 Award.

2004 - Finalist for the 2004 Collegiate Inventors Competition. National Inventors Hall of Fame, Akron, Ohio.

Organizations

American Society of Bone and Mineral Research (2011-Present)

American Dental Education Association (2009-Present)

American Association of Anatomy (2007-Present)

American Association of Dental Research (2005-Present)

Egyptian Physician Syndicate (1994-Present)

Selected Publications

Elsayed R, Kurago Z, Cutler CW, Arce RM, Gerber J, Celis E, Sultan H, Elashiry M, Meghil M, Sun C, Auersvald CM, Awad ME, Zeitoun R, Elsayed R, Eldin M Elshikh M, Isales C, Elsalanty ME. Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw. FASEB J. 2020 Feb;34(2):2595-2608. doi: 10.1096/fj.201901819RR. Epub 2020 Jan 9. PMID: 31919918

Awad ME, Sun C, Jernigan J, Elsalanty M. Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis. J Am Dent Assoc. 2019 Aug;150(8):664-675.e8. doi:10.1016/j.adaj.2019.03.006. Epub 2019 Jun 28. PMID: 31256803; PMCID: PMC6839407.

Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. EPMA J. 2019 Jan 24;10(1):21-29. doi: 10.1007/s13167-019-0160-3. eCollection 2019 Mar. PubMed PMID: 30984311; PubMed Central PMCID: PMC6459452

Awad, ME; Altman, A; Elrefai,R; Shipman, P; Looney, S; Elsalanty. The Use of Vascularized fibula flap in Mandibular reconstruction; A comprehensive systematic review and Meta-analysis of the observational studies.Journal of Craniomaxillofacial surgery.

Elsayed R, Abraham P, Awad ME, Kurago Z, Baladhandayutham B, Whitford GM, Pashley DH, McKenna CE,ElsalantyME. Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. Bone. 2018 Feb 8;110:141-149. doi: 10.1016/j.bone.2018.01.030. [Epub ahead of print] PMID:29408511

Howie RN, Bhattacharyya M, Salama ME, Refaey ME, Isales C, Borke J, Daoudi A, Medani F, Elsalanty ME. Removal of pamidronate from bone in rats using systemic and local chelation. Arch Oral Biol. 2015 Sep 7;60(12):1699-1707. doi: 10.1016/j.archoralbio.2015.09.001. [Epub ahead of print] PMID: 26431826

Howie RN, Borke JL, Kurago Z, Daoudi A, Cray J, Zakhary IE, Brown TL, Raley JN, Tran LT, Messer R, Medani F, Elsalanty ME. A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma. PLoS One. 2015 Jul 17;10(7):e0132520. doi: 10.1371/journal.pone.0132520. eCollection 2015. PMID: 26186665

Book Chapter: Elsalanty, ME. Bone Development and Histogenesis of the Jaw. In Tolstunov, L (Editor). Horizontal alveolar ridge augmentation in implant dentistry, 1st Edition, Wiley Blackwell, Inc. 2016

Educational Publications: Elsalanty M. Early Tooth Development. MedEdPORTAL; 2012. Available from: www.mededportal.org/publication/9169

Full List of Publication:https://pubmed.ncbi.nlm.nih.gov/?term=Elsalanty&sort=date

Selected Invited Talks

• Osteoporosis treatment: from patients to cells and back. Biomedical Engineering Society Annual Meeting (BMES) 2018, Atlanta, GA, USA
• Symposium Chair: Future of Osteoporosis Treatment. Experimental Biology 2018, San Diego, CA, USA
• Symposium Chair: Bone Remodeling in Health, Disease, and Aging. Experimental Biology 2017, Chicago, USA
• Invited lecture: Bone tissue regeneration in the craniomaxillofacial skeleton. April 5th, 2017, Sheikh Zayed Hospital, Cairo, Egypt.
• Invited lecture: Bisphosphonate-related osteonecrosis of the jaw: a preventable condition? March 31st, 2017, Heliopolis Hospital, Cairo, Egypt

US PATENTS and Entrepreneurship:

1. A novel bone transport distraction device for reconstruction of mandibular bone defects and the method for its use. The device is called “Mandibular Bone Transport Reconstruction Plate (BTRP)”. Testing and development of the device is being carried out with support of two NIH grants. US Patent # 7,182,785 (Awarded February 2007); 510(K) awarded May 2007.
2. Improved mandibular bone transport mechanism; awarded to Craniotech ACR Devices (US Patent # 11,670,311, awarded 2011; and # 8,287,573, awarded October 15, 2012)
3. Co-founder and co-owner:

• Craniotech ACR Devices, LLC, a research and development company for dental and maxillofacial devices based in Dallas, TX, USA.
• Southeastern Biotech, LLC, research and development company, Augusta, GA, USA